Arcutis Biotherapeutics 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Welcome, everybody, and thanks for joining us again at Guggenheim's Healthcare Innovation Conference. I'm Seamus Fernandez, one of the senior biopharma analysts here at Guggenheim, and I'm really pleased to be joined again this year by Arcutis Biotherapeutics. To my immediate left is Frank Watanabe, President and CEO, Rob Lisicki, the newly appointed CCO, and Latha Vairavan, CFO. Again, going from left to left to left. Maybe Frank, let's just kind of get started here. It's been a great year, obviously, for Arcutis and ZORYVE. You've raised 2026 guidance twice, and gave it for the first time earlier this year. But in terms of just what's driving the outperformance from your perspective, relative to that original guidance, what is it, and how are you looking forward into 2027?
I think the performance in 2026 really is the same reason we saw strong performance in prior years. I think it's threefold. The first one is the product profile itself. As you know from your doctor talks, this is a product that's very well-suited to what clinicians and patients are looking for, both in terms of efficacy and safety, tolerability, and convenience. So, it's filling a really important need in the marketplace, and that's what's driven, I think, our very, very high share of the branded non-steroidal market. That's factor number one. Factor number two is, I think, as you know, we're dealing in very, very large markets that have been historically dominated by topical steroids, but there's this ongoing shift away from topical steroids because of all the safety concerns with long-term steroid use in these chronic conditions.
Then the third thing, I think the team is, we have an outstanding team. We continue to attract top talent. Rob's addition to the team has been fantastic. We've known each other for decades. Very, very experienced dermatology commercial leader. But, I think across the board, the strength of our team along with the large market and the really differentiated product profile has been what has continued to drive the very strong performance of ZORYVE. I think in 2027, as we look to 2027, that is just going to continue. Then, we have some really important catalysts that we think are going to translate into even further growth in 2027. We expanded the dermatology sales team in 2026. We're starting to see the impact of that now, and I think that'll continue on through 2027. We've started building out the primary care and pediatric team.
We haven't really seen much impact from that yet because it's still very early days. We're only about three months in to the peds and PCP team. But I think in 2027, that'll be an important driver. In addition to that, we signed the recent deal with Simone Biles to be one of our spokespeople. She's a fantastic brand ambassador. We're very excited about her raising awareness about both seborrheic dermatitis and eczema, and ZORYVE as an opportunity, a new opportunity to treat those conditions. Then lastly, we've got the pediatric approval coming up at the end of February, which we think is going to be a really important catalyst for growth in 2027.
You are taking a very strong business with good momentum going into 2027, then you are layering on top of that a number of very important catalysts. That is really what has led us to this confidence, bullishness about 2027 and beyond that we have talked about in some of our previous conversations.
Great. Fourth quarter is seasonally, so far, been consistently the strongest quarter. Is there anything that we should keep in mind about this fourth quarter in particular that could possibly be different in any way, shape, or form? Then should we anticipate the sort of standard seasonality, the dip post-fourth quarter?
Yeah. Nothing to us would suggest that Q4 of 2026 is going to look any different than any other typical Q4. It does tend to be the strongest quarter of the year. The only, I think, comment I would make, just as in Q3, we do not expect to see much in terms of price. We got to our steady state gross-to-net very early this year.
Yeah. I cannot exactly say why other than patients were spending more on healthcare apparently this year.
We very quickly got to steady state, and that is why we did not see much price effect in Q3, and you would not expect to see much price in Q4 either. You should see some nice volume growth.
Okay, great. So, maybe a question for Rob. As you sort of come in with your extensive experience, and the time obviously working on Enbrel with Frank, you called ZORYVE's share so far merely the tip of the iceberg. What really surprised you most when you looked under the hood? What do you see as kind of the untapped near-term opportunities in particular?
Yeah. On the surprise, I'd say two things. One is, externally, it's always hard to measure the esprit de corps of a company. The culture of the company is really special, unique. Everyone has a shared vision and purpose, and companies that have that do perform well. I think on this, the other surprise would be the development success. When you look at the number of phase II, phase III successfully completed studies in such a rapid timeframe, it's hard to find large companies that have that success. On the opportunity piece, I think the iceberg analogy is perfect. When you think of an iceberg, you see 10% of it above the water, 90% is below. That's where we are right now, for branded non-steroidals.
We're going to exit the year with 10% of the market being branded non-steroidal, so 90% of the opportunity is in front of us. The way we get that is through additional indication work. We have studies in vitiligo and HS. We have the AD infant indication coming in March. The other is we announced about a week ago a phase III study in AD moderate to severe. Assuming success with all of those studies, you have an asset that essentially can be used cradle to cane, in the AD space. Regardless of mild, moderate, or severe, regardless of BSA coverage, and regardless of systemic or biologic use, all of those things, I think, offer the product an extremely exciting future.
What are the aspects, Frank, that unlock the opportunity that we've talked about? I think the street continues to not quite get to the $2.5 billion-$3.5 billion. I think mentally, when we just sort of look at the market, one can get there actually pretty easily.
Yep. But there's this barrier of, "Wow, no topical has done that before." So, what is different this time?
Well, I think- It helps to have a product that works.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
4 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
